Literature DB >> 22493439

Influenza virus partially counteracts restriction imposed by tetherin/BST-2.

Bastien Mangeat1, Lorris Cavagliotti, Martin Lehmann, Gustavo Gers-Huber, Inderdeep Kaur, Yves Thomas, Laurent Kaiser, Vincent Piguet.   

Abstract

Influenza virus infections lead to a burst of type I interferon (IFN) in the human respiratory tract, which most probably accounts for a rapid control of the virus. Although in mice, IFN-induced Mx1 factor mediates a major part of this response, the situation is less clear in humans. Interestingly, a recently identified IFN-induced cellular protein, tetherin (also known as CD317, BST-2, or HM1.24), exerts potent antiviral activity against a broad range of retroviruses, as well as several other enveloped viruses, by impeding the release of newly generated viral particles from the cell surface. Here we show that influenza virus belongs to the targets of this potent antiviral factor. Ectopic expression of tetherin strongly inhibited fully replicative influenza virus. In addition, depleting endogenous tetherin increased viral production of influenza virions, both in cells constitutively expressing tetherin and upon its induction by IFN. We further demonstrate, by biochemical and morphological means, that tetherin exerts its antiviral action by tethering newly budded viral particles, a mechanism similar to the one that operates against HIV-1. In addition, we determined that the magnitude of tetherin antiviral activity is comparable with or higher than the one of several previously identified anti-influenza cellular factors, such as MxA, ADAR1, ISG15, and viperin. Finally, we demonstrate that influenza virus reduces the impact of tetherin-mediated restriction on its replication by several mechanisms. First, the influenza virus NS1 protein impedes IFN-mediated tetherin induction. Second, influenza infection leads to a decrease of tetherin steady state levels, and the neuraminidase surface protein partly counteracts its activity. Overall, our study helps to delineate the intricate molecular battle taking place between influenza virus and its host cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493439      PMCID: PMC3381161          DOI: 10.1074/jbc.M111.319996

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

Review 1.  Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences.

Authors:  Thorsten Wolff; Stephan Ludwig
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

2.  Cutting edge: stealth influenza virus replication precedes the initiation of adaptive immunity.

Authors:  Bruno Moltedo; Carolina B López; Michael Pazos; María Inés Becker; Tamar Hermesh; Thomas M Moran
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

3.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

4.  Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.

Authors:  Anna Le Tortorec; Stuart J D Neil
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

5.  Blocking interhost transmission of influenza virus by vaccination in the guinea pig model.

Authors:  Anice C Lowen; John Steel; Samira Mubareka; Elena Carnero; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

6.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.

Authors:  Eri Miyagi; Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

7.  Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.

Authors:  Matthew W McNatt; Trinity Zang; Theodora Hatziioannou; Mackenzie Bartlett; Ismael Ben Fofana; Welkin E Johnson; Stuart J D Neil; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

8.  HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.

Authors:  Bastien Mangeat; Gustavo Gers-Huber; Martin Lehmann; Madeleine Zufferey; Jeremy Luban; Vincent Piguet
Journal:  PLoS Pathog       Date:  2009-09-04       Impact factor: 6.823

9.  The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.

Authors:  Abraham L Brass; I-Chueh Huang; Yair Benita; Sinu P John; Manoj N Krishnan; Eric M Feeley; Bethany J Ryan; Jessica L Weyer; Louise van der Weyden; Erol Fikrig; David J Adams; Ramnik J Xavier; Michael Farzan; Stephen J Elledge
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

10.  Tetherin inhibits HIV-1 release by directly tethering virions to cells.

Authors:  David Perez-Caballero; Trinity Zang; Alaleh Ebrahimi; Matthew W McNatt; Devon A Gregory; Marc C Johnson; Paul D Bieniasz
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

View more
  43 in total

1.  Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.

Authors:  Victor H Leyva-Grado; Rong Hai; Fiona Fernandes; Alan Belicha-Villanueva; Carol Carter; Mark A Yondola
Journal:  J Mol Biol       Date:  2013-12-29       Impact factor: 5.469

2.  BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1).

Authors:  Philip H Jones; Martina Maric; Marisa N Madison; Wendy Maury; Richard J Roller; Chioma M Okeoma
Journal:  Virology       Date:  2013-02-12       Impact factor: 3.616

3.  BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer.

Authors:  Philip H Jones; Wadie D Mahauad-Fernandez; Marisa N Madison; Chioma M Okeoma
Journal:  Virology       Date:  2013-06-25       Impact factor: 3.616

4.  Identification of Interferon-Stimulated Gene Proteins That Inhibit Human Parainfluenza Virus Type 3.

Authors:  M A G Rabbani; Michael Ribaudo; Ju-Tao Guo; Sailen Barik
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

5.  Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase.

Authors:  Kerstin Gnirß; Pawel Zmora; Paulina Blazejewska; Michael Winkler; Anika Lins; Inga Nehlmeier; Sabine Gärtner; Anna-Sophie Moldenhauer; Heike Hofmann-Winkler; Thorsten Wolff; Michael Schindler; Stefan Pöhlmann
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

6.  The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.

Authors:  Ran Yan; Xuesen Zhao; Dawei Cai; Yuanjie Liu; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

7.  Proteomic analysis reveals down-regulation of surfactant protein B in murine type II pneumocytes infected with influenza A virus.

Authors:  Lemme P Kebaabetswe; Anoria K Haick; Marina A Gritsenko; Thomas L Fillmore; Rosalie K Chu; Samuel O Purvine; Bobbie-Jo Webb-Robertson; Melissa M Matzke; Richard D Smith; Katrina M Waters; Thomas O Metz; Tanya A Miura
Journal:  Virology       Date:  2015-05-15       Impact factor: 3.616

Review 8.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

9.  Tetherin Antagonism by HIV-1 Group M Nef Proteins.

Authors:  Juan F Arias; Marta Colomer-Lluch; Benjamin von Bredow; Justin M Greene; Julie MacDonald; David H O'Connor; Ruth Serra-Moreno; David T Evans
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

10.  Tetherin upregulation in simian immunodeficiency virus-infected macaques.

Authors:  Andrew R Rahmberg; William J Neidermyer; Matthew W Breed; Xavier Alvarez; Cecily C Midkiff; Michael Piatak; Jeffrey D Lifson; David T Evans
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.